Bendamustine for the first-line treatment of chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • TA216
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Peninsula Technology Assessment Group:

  • Hoyle M, Crathorne L, Jones-Hughes T et al. Bendamustine for the first-line treatment of chronic lymphocytic leukaemia, October 2010.

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope. Organisations listed in I were also invited to make written submissions. Organisations listed in II gave their expert views on bendamustine for the treatment of chronic lymphocytic leukaemia by providing a written statement to the Committee. Organisations listed in I, II and III have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • Napp Pharmaceuticals

II) Professional/specialist and patient/carer groups:

  • British Society for Haematology

  • Cancer Research UK

  • Chronic Lymphocytic Leukaemia Support Association (CLLSA)

  • Leukaemia CARE

  • Lymphoma Association

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • United Kingdom Chronic Lymphocytic Leukaemia Forum

III) Other consultees:

  • Department of Health

  • Welsh Assembly Government

IV) Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Leukaemia & Lymphoma Research

  • National Collaborating Centre for Cancer

  • National Institute for Health Research Health Technology Assessment Programme

  • NHS Quality Improvement Scotland

  • Peninsula Technology Assessment Group, University of Exeter (PenTAG)

C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on bendamustine for the treatment of chronic lymphocytic leukaemia by providing oral evidence to the Committee.

  • Dr Chris Fegan, nominated by Royal College of Physicians, NCRI, RCR, ACP, JCCO – clinical specialist

  • Professor Andrew Pettitt, nominated by Royal College of Pathologists and United Kingdom Chronic Lymphocytic Leukaemia Forum – clinical specialist

  • Jane Barnard, nominated by Chronic Lymphocytic Leukaemia Support Association – patient expert

  • Chonette Taylor, nominated by Chronic Lymphocytic Leukaemia Support Association – patient expert

D. Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Napp Pharmaceuticals